Introduced in 1987, prostate-antigen screening (PSA) has resulted in over 1 million additional men being diagnosed and treated for prostate cancer – but most of these were likely overdiagnosed and should not have been treated, a new study in the Journal of the National Cancer Institute contends.
Using data from the National Cancer Institute, H. Gilbert Welch, of The Dartmouth Institute for Health Policy & Clinical Practice, and Peter C. Albertsen, of the University of Connecticut, examined age-specific prostate cancer incidence rates to determine the excess (or deficit) in the number of American men diagnosed and treated in each year after 1986. They found that an additional 1.3 million men were diagnosed – that would otherwise have never been diagnosed absent screening – and more than 1 million have been treated.
“Given the considerable time that has passed since PSA screening began, most of this excess incidence must represent overdiagnosis,” the researchers argue. “All overdiagnosed patients are needlessly exposed to the hassle factors of obtaining treatment, the financial implications of the diagnosis, and the anxieties associated with becoming a cancer patient.”
The study suggests that while screening practices for prostate cancer have surged over the last 20 years, there is little evidence that it has saved lives. The researchers contend that the highly pushed early-detection message has skewed public opinion and de-legitimized the questions concerning screening, causing many men to be overdiagnosed.
“We desperately need the ability to predict which patient has a localized cancer that is going to metastasize and cause suffering and death and which patient has a cancer that is destined to stay in the patient’s prostate for the remainder of his life,” noted Otis W. Brawley, chief medical officer of the American Cancer Society, in a commentary to the study.